Modality
mAb
MOA
HPK1i
Target
FGFR
Pathway
Autophagy
TTR AmyloidosisADHD
Development Pipeline
Preclinical
~Feb 2016
→ ~May 2017
Phase 1
~Aug 2017
→ ~Nov 2018
Phase 2
~Feb 2019
→ ~May 2020
Phase 3
Aug 2020
→ Oct 2028
Phase 3Current
NCT03762040
190 pts·ADHD
2020-08→2025-07·Completed
NCT07332756
2,038 pts·ADHD
2021-08→2025-08·Not yet recruiting
NCT06497788
150 pts·ADHD
2025-11→2028-10·Terminated
2,378 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-07-198mo agoPh3 Readout· ADHD
2025-08-157mo agoPh3 Readout· ADHD
2028-10-042.5y awayPh3 Readout· ADHD
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P3
Complet…
P3
Not yet…
P3
Termina…
Catalysts
Ph3 Readout
2025-07-19 · 8mo ago
ADHD
Ph3 Readout
2025-08-15 · 7mo ago
ADHD
Ph3 Readout
2028-10-04 · 2.5y away
ADHD
CompletedTerminatedNot yet recruiting|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03762040 | Phase 3 | ADHD | Completed | 190 | Safety |
| NCT07332756 | Phase 3 | ADHD | Not yet recr... | 2038 | EASI-75 |
| NCT06497788 | Phase 3 | ADHD | Terminated | 150 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| Cevitinib | Regeneron | Phase 3 | FGFR | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| BII-5240 | Biogen | Phase 2/3 | MALT1 | |
| Semasacituzumab | Illumina | Phase 3 | Nectin-4 |